Characteristics and Clinical Outcomes of Extended-Spectrum beta-lactamase-producing Klebsiella pneumoniae Bacteremia in Cancer Patients
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Cancer patients can be at a higher risk of infection due to drug-resistant bacteria than the general population for various reasons. We performed a retrospective study to evaluate possible risk factors and outcomes of extended-spectrum beta-lactamaseproducing Klebsiella pneumoniae (ESBL-KP) bacteremia in cancer patients. Materials and Methods: Cases were divided into two groups based on whether or not the isolated strain produced ESBL and multivariable regressions were done to identify possible risk factors of ESBL-KP bacteremia and mortality. For ESBL-producing strain, additional molecular analysis was done. Results: 278 cases with KP bacteremia were identified between 2010 and 2012, of which ESBLproducers were 50 (18%). The presence of percutaneous drainage catheter [odds ratio (OR) 4.99, P <0.001] and prior exposure to certain classes of antibiotics including third-generation cephalosporin (OR 2.14, P = 0.03) had significant associations with ESBL-KP bacteremia. Individuals who died within 14 days after the onset of KP bacteremia were more likely to have higher mean Pitt bacteremia score (1.56 in survival group vs. 3.43 in mortality group, P <0.001), hemodialysis (OR 17.03, P = 0.01) and chronic liver disease (OR 5.57, P = 0.01). Although 14-day mortality was higher with ESBL production (OR 2.76, P = 0.04), no significant differences in 30- day mortality (OR 1.67, P = 0.20) and other morbidity indices were observed. 49 ESBL-KP isolates, 65.4% of them produced CTX-M-14 and CTX-M-15 enzymes, and ST711 was the most common. Conclusion: There were several differences in clinical characteristics between ESBL-KP and nonESBL-KP bacteremia in cancer patients, similar to previous reports including non-cancer patients.
Abstract
Background: Cancer patients can be at a higher risk of infection due to drug-resistant bacteria than the general population for various reasons. We performed a retrospective study to evaluate possible risk factors and outcomes of extended-spectrum beta-lactamaseproducing Klebsiella pneumoniae (ESBL-KP) bacteremia in cancer patients. Materials and Methods: Cases were divided into two groups based on whether or not the isolated strain produced ESBL and multivariable regressions were done to identify possible risk factors of ESBL-KP bacteremia and mortality. For ESBL-producing strain, additional molecular analysis was done. Results: 278 cases with KP bacteremia were identified between 2010 and 2012, of which ESBLproducers were 50 (18%). The presence of percutaneous drainage catheter [odds ratio (OR) 4.99, P <0.001] and prior exposure to certain classes of antibiotics including third-generation cephalosporin (OR 2.14, P = 0.03) had significant associations with ESBL-KP bacteremia. Individuals who died within 14 days after the onset of KP bacteremia were more likely to have higher mean Pitt bacteremia score (1.56 in survival group vs. 3.43 in mortality group, P <0.001), hemodialysis (OR 17.03, P = 0.01) and chronic liver disease (OR 5.57, P = 0.01). Although 14-day mortality was higher with ESBL production (OR 2.76, P = 0.04), no significant differences in 30- day mortality (OR 1.67, P = 0.20) and other morbidity indices were observed. 49 ESBL-KP isolates, 65.4% of them produced CTX-M-14 and CTX-M-15 enzymes, and ST711 was the most common. Conclusion: There were several differences in clinical characteristics between ESBL-KP and nonESBL-KP bacteremia in cancer patients, similar to previous reports including non-cancer patients.
참고문헌 (31)
- Montassier E, "Recent changes in bacteremia in patients with cancer : a systematic review of epidemiology and antibiotic resistance", Eur J Clin Microbiol Infect Dis, 32, pp.841~850 (2013)
- Podschun R, "Klebsiella spp. as nosocomial pathogens : epidemiology, taxonomy, typing methods, and pathogenicity factors", Clin Microbiol Rev, 11, pp.589~603 (1998)
- Chetcuti Zammit S, "Mortality risk score for Klebsiella pneumoniae bacteraemia", Eur J Intern Med, 25, pp.571~576 (2014)
- Paterson DL, "Extended-spectrum beta-lactamases : a clinical update", Clin Microbiol Rev, 18, pp.657~686 (2005)
- Schneeweiss S, "Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis", Arthritis Rheum, 56, pp.1754~1764 (2007)
- Smitten AL, "The risk of hospitalized infection in patients with rheumatoid arthritis", J Rheumatol, 35, pp.387~393 (2008)
- Friedman ND, "Health care--associated bloodstream infections in adults : a reason to change the accepted definition of community-acquired infections", Ann Intern Med, 137, pp.791~797 (2002)
- Paterson DL, "Antibiotic therapy for Klebsiella pneumoniae bacteremia : implications of production of extended-spectrum beta-lactamases", Clin Infect Dis, 39, pp.31~37 (2004)
- Charlson ME, "A new method of classifying prognostic comorbidity in longitudinal studies : development and validation", J Chronic Dis, 40, pp.373~383 (1987)
- Khwaja A, "KDIGO clinical practice guidelines for acute kidney injury", Nephron Clin Pract, 120, pp.c179~84 (2012)
- Mermel LA, "Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection : 2009 Update by the Infectious Diseases Society of America", Clin Infect Dis, 49, pp.1~45 (2009)
- Lee JA, "Epidemiology and clinical features of community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae", Microb Drug Resist, 17, pp.267~273 (2011)
- Tumbarello M, "Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae : risk factors, molecular epidemiology, and clinical outcome", Antimicrob Agents Chemother, 50, pp.498~504 (2006)
- Tuon FF, "Klebsiella ESBL bacteremia-mortality and risk factors", Braz J Infect Dis, 15, pp.594~598 (2011)
- Paterson DL, "International prospective study of Klebsiella pneumoniae bacteremia : implications of extended-spectrum beta-lactamase production in nosocomial Infections", Ann Intern Med, 140, pp.26~32 (2004)
- Mosqueda-Gómez JL, "Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae A case-control study", Int J Infect Dis, 12, pp.653~659 (2008)
- Chopra T, "Risk factors for bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae : A focus on antimicrobials including cefepime", Am J Infect Control, 43, pp.719~723 (2015)
- Lee SO, "Reduced use of third-generation cephalosporins decreases the acquisition of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae", Infect Control Hosp Epidemiol, 25, pp.832~837 (2004)
- Superti SV, "Risk factors for and mortality of extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli nosocomial bloodstream infections", Rev Inst Med Trop Sao Paulo, 51, pp.211~216 (2009)
- Harris AD, "Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance : a systematic review", Clin Infect Dis, 32, pp.1055~1061 (2001)
- Harris AD, "Control-group selection importance in studies of antimicrobial resistance : examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli", Clin Infect Dis, 34, pp.1558~1563 (2002)
- Lautenbach E, "Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae : risk factors for infection and impact of resistance on outcomes", Clin Infect Dis, 32, pp.1162~1171 (2001)
- Paterson DL, "Looking for risk factors for the acquisition of antibiotic resistance : a 21st-century approach", Clin Infect Dis, 34, pp.1564~1567 (2002)
- Lin YT, "Nosocomial Klebsiella pneumoniae bacteraemia in adult cancer patients--characteristics of neutropenic and non-neutropenic patients", Scand J Infect Dis, 43, pp.603~608 (2011)
- Cosgrove SE, "The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs", Clin Infect Dis, 42(Suppl 2), pp.S82~S89 (2006)
- Johnson JR, "Virulence characteristics and phylogenetic background of multidrug-resistant and antimicrobial-susceptible clinical isolates of Escherichia coli from across the United States, 2000-2001", J Infect Dis, 190, pp.1739~1744 (2004)
- Melzer M, "Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli", J Infect, 55, pp.254~259 (2007)
- Marra AR, "Nosocomial bloodstream infections caused by Klebsiella pneumoniae : impact of extended-spectrum beta-lactamase(ESBL)production on clinical outcome in a hospital with high ESBL prevalence", BMC Infect Dis, 6, pp.24~ (2006)
- Kim BN, "Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia", J Hosp Infect, 52, pp.99~106 (2002)
- Hyle EP, "Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae : variability by site of infection", Arch Intern Med, 165, pp.1375~1380 (2005)
- Tumbarello M, "Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae : importance of inadequate initial antimicrobial treatment", Antimicrob Agents Chemother, 51, pp.1987~1994 (2007)